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The aim of the study was to assess the patterns of development of metachronous cancer (endometrial cancer, EC, and ovarian 
cancer, OC) in breast cancer (BC) patients dependent of receptor phenotype of breast tumors. Materials and Methods: In the 
study, 63 patients with ВС, who developed metachronous EC (n = 47) or OC (n = 16) were enrolled. Expression of estrogen re-
ceptor (ER), progesterone receptor (PR), HER/2neu was assessed using immunohistochemical approach. Results: BC in patients 
with metachronous EC and OC was characterized by a different frequency of molecular subtypes with the dominance of luminal 
A (36%) and B (43%) subtypes. In primary BC, we have established a correlation between ER expression and regional lymph 
nodes status (r = −0.50, p < 0.05); negative correlation between HER2/neu expression and tumor stage (r = −0.48, p < 0.05); 
between the molecular subtype of BC and its size (r = −0.33, p <0.05), the molecular subtype of primary BC and metastases 
in regional lymph nodes (r = 0.27, p <0.05). In the patients with luminal subtype BC metachronous tumors developed with the 
highest frequency (OC — 50%, EC — 50%). After treatment of primary BC metachronous tumors developed at different period: 
EC (22.2%) — most often in 3–5 years, OC (11.0%) — after 10 years and more. Conclusion: Our data evidence on the clinical 
significance of the individual characteristics of the BC, especially its molecular subtype, and the need to calculate the personalized 
risk of development of metachronous tumors of the reproductive system in patients with the BC.
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Over recent years, breast cancer (BC) has re-
mained the most common malignant disease among 
women both in Ukraine and in most countries of West-
ern Europe and America. Analyzing the survival rates 
of patients with BC in recent decades, one may 
conclude that improvement of BC treatment results 
is achieved. According to Surveillance, Epidemiology 
and End Results data, the statistical database of the 
National Cancer Institute in the USA, 5-year survival 
constitutes 83.4–98.4% in case of localized forms 
of BC and 23.3% in case of metastatic BC. Such results 
have been achieved due to a personified approach 
to BC treatment [4].
The emergence of metachronous tumors, namely 
ВС, еndometrial cancer (EC) and ovarian cancer (OC), 
has become particularly relevant over the last decade. 
Numerous studies have shown that BC is a hormone-
dependent cancer associated with a chronic effect 
of estrogens related to an impaired estrogen-proges-
terone balance. According to the estrogen theory, es-
trogens and their receptors play an essential role in the 
initiation and promotion of the process of malignant 
transformation, since hyperestrogenism is one of the 
factors modulating genes expression leading to dys-
regulation of cellular signaling and the development 
of metachronous BC [1–4].
A well-known fact is that BC represents a hetero-
geneous tumor group. According to the molecular 
genetic classification, four subtypes of BC are dis-
tinguished: luminal A, luminal B, HER-2/neu positive, 
basal or triple-negative. According to modern studies, 
the presence of steroid hormones receptors is an im-
portant biological feature of malignant tumors and can 
determine the course of the disease. In addition, the 
disruption of hormonal balance in the body of women 
is also associated with the ЕС and ОС onset. Clinical 
course of hormone related tumors depends on de-
crease or loss of expression of both progesterone 
receptors (PR) and estrogen receptors (ER), which 
manifests itself in a greater aggressiveness of the 
tumor process: more invasion, metastasis and unfa-
vorable course of disease [5–7]. But at present time, 
no clear relation between the clinical-biological fea-
tures of BC receptor phenotype and the development 
of subsequent metachronous hormone related can-
cers has been established. The above mentioned data 
suggest the expediency of studying the ER, PR and 
HER-2/neu status in patients with primary BC tumors 
and metachronous OC and EC. This will allow to assess 
the receptor status in these neoplasms and evaluate 
its significance in the course of the tumor disease.
MATERIALS AND METHODS
In the study, 63 patients with BC, in which, after 
the completion of treatment, another oncological 
disease has developed, were enrolled: EC deve-
loped in 47 patients, OC — in 16 patients. The study 
did not include BC patients with BC progression 
or metastasis. The verification of BC and the second 
oncological disease was carried out by histological 
examination of the biopsy and/or surgical material 
of biological specimens. The clinical diagnostics 
of BC was performed according to the TNM clas-
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sification (2002) and the diagnostics of second 
oncological disease was carried out by histologi-
cal examination (World Health Organization, 2003) 
of the biopsy and/or surgical material of biological 
specimens.
The patients received combined treatment: sur-
gical, chemotherapeutic, radiological, hormonal 
therapy (if necessary). 86% of patients received 
hormone therapy with tamoxifen (20 mg once a day 
for 5 years). All patients were cured at the Communal 
Institution “Precarpathian Clinical Cancer Center” 
from 1986 to 2016, treatment, according to the order 
of the Ministry of Health of Ukraine No. 396 “On Ap-
proval and Implementation of Medical-Technological 
Documents for the Standardization of Medical Assis-
tance of Cancer Patients”. The study was approved 
by the Ethics Commission of Ivano-Frankivsk National 
Medical University (conclusion No. 83).
To assess ER, PR and HER2/neu expression 
in the samples of BC, EC and OC, 4 µm histologic 
slides were prepared from paraffin blocks of tumors. 
Immunohistochemical study was performed using 
the following monoclonal antibodies: antiER — clone 
1D5, antiPR — clone PgR636, antiHER/2neu — clone 
c-erbB-2 (Dako Cytomation, Denmark). The degree 
of immunohistochemical reaction was assessed 
as «+++» — strong, «++» — moderate, «+» — low 
or no expression (0). The number of cells with 
> 10% with a strong and moderate expression was 
considered as positive expression of the examined 
markers.
The statistical analysis of the data was performed 
using Microsoft® Office Excel® 2007 and Statis-
tica v.6.1 (Statsoft Inc., USA) programs for variation 
statistics, correlation, regression, multiple correla-
tion-regression analysis. Changes were considered 
to be significant at p < 0.05.
RESULTS AND DISCUSSION
The conducted research is based on the results 
of clinical and immunohistochemical investigation 
of 63 patients with BC, in which after the comple-
tion of treatment, another oncological disease was 
arized (ЕС or ОС). The age of BC patients varied 
from 25 to 83 years (at average 53.9 ± 11.8 years) 
(Table 1). BC cases were assessed according 
to the TNM classification (2002) (Table 2), and 
BC was mostly of stages I and II (27.0 and 50.8%, 
respectively), and stage III (19.0%). All 63 patients 
with BC were operated because of the second 
oncological disease: EC developed in 47 patients, 
OC — in 16 patients.
Table 1. Distribution of patients with primary BC by age
Age, years n = 63 100%
25 1 1.6
30–39 6 9.5
40–49 12 19.0
50–59 18 28.6
60–69 15 23.8
70–79 9 14.3
80–83 2 3.3
Total 63 100.0
Average age 53.9 ± 11.8
Table 2. Distribution of patients with primary BC according to TNM clas-
sification (2002)
Stage of primary BC n %
I stage: Т1N0М0 17 27.0
II stage: T0–3N0–1M0 32 50.8
III stage: T0–4N0–3M0 12 19.0
IV stage: T0–4N0–3M1 2 3.2
Total 63 100.0
All patients underwent surgical treatment. Mastec-
tomy by Madden was performed in 36 (57.2%) patients 
with BC, mastectomies by Halstead — in 14 (22.2%), 
and by Petit — in 9 (14.3%). Organ-preserving opera-
tion (quadrantectomy) was done in 4 (6.3%) patients 
(Table 3).
Table 3. Distribution of patients with primary BC according to surgical 
treatment
Surgical trearment n %
Quadrantectomy 4 6.3
Mastectomy by Maden 36 57.2
Mastectomy by Petit 9 14.3
Mastectomy by Halsted 14 22.2
Total 63 100.0
After surgical treatment 86% of patients received 
hormone therapy (tamoxifen 20 mg once a day for 
5 years). Metachronous EC occurred mainly in the pe-
riod from 3 to 5 years after the treatment of BC (14 pa-
tients (22.2%)), and metacharonic OC — in period 
longer than 10 years (in 7 patients (11.0%)) (Table 4).
Table 4. Period of development of metachronous ЕС and OC
Cases of development of metachronous tumors after treatment  
of primary BC (n = 63/100%)
Terms after treatment
of BC
EC, n (%)
47 (74.6)
OC, n (%)
16 (25.4)
Up to 1 year 6 (9.5) 1 (1.6)
From 1 to 3 years 5 (7.9) 2 (3.2)
From 3 to 5 years 14 (22.2) 3 (4.8)
From 5 to 10 years 10 (15.9) 3 (4.8)
More than 10 years 12 (19.1) 7 (11.0)
The stage of the metachronous tumors was the fol-
lowing: EC was of stage I in 34 (54.0%) cases, stages 
II and III — in 9 (14.3%) and 4 (6.3%) cases, respec-
tively; OC — of stage III in 8 (12.7%) cases, stage II — 
in 5 (7.9%) cases, and stage I — in 3 (4.8%) patients.
According to the immunohistochemical features, 
the breast tumors were of 4 molecular subtypes: lu-
minal A subtype constituting 36%; luminal B subtype 
with the highest frequency constituting 43%; Her2/
neu-positive subtype — 7%; and basal-like subtype 
(or triple-negative subtype, ER−PR−Hеr2/neu−) — 
14% cases (Table 5). In the patients with luminal 
subtype BC metachronous tumors developed with the 
highest frequency (OC — 50%, EC — 50%).
One of the most important clinical characteristics 
is the presence of metastases in RLN or organs distant 
from the tumor. In the majority of patients with BC they 
were absent regardless of the tumor molecular sub-
type: luminal A — 67.9%, luminal B — 68.6%, triple 
negative — 85.7%.
Statistical analysis of the data showed that there 
is a significant correlation between ER expression 
and RLN status (r = −0.50, p < 0.05); expression 
of HER2/neu and the stage of the disease (r = −0.48, 
p < 0.05). The relation between the molecular subtype 
of the primary BC with its size (r = −0.33, p < 0.05) and 
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the presence of metastases in RLN (r = 0.27, p < 0.05) 
were also found.
It seemed appropriate to analyze further the re-
lation between ER, PR and HER2/neu expression 
in these patients with the clinical and pathological 
features of tumor growth which are important for the 
estimation of the disease prognosis: stage, tumor size, 
metastases of RLN, BC molecular subtype.
The largest number of ER+ and HER2/neu-positive 
tumors was detected in patients with stage I (100% and 
100%, respectively) of both BC and EC in comparison 
with stages II and III of BC and EC (83 and 54%, respec-
tively); in patients with BC and EC of stage II or III — 
67 and 33%, respectively. The significant difference 
in PR expression depending on the stage of the tumor 
process was not detected. The statistical analysis 
of the data indicated the existence of an inverse re-
lationship between ER, Her2/neu expression and the 
disease stage. Positive expression of steroid hormone 
receptors was detected in 12 and 50% of patients with 
stages II and III of metachronous OC.
Recurrence-free and overall survival is in reverse 
correlation with RLN metastases [7–11]. Taking this 
into consideration, we conducted a research on the 
relation between the receptor status of BC, EC and 
OC tumor cells and metastasis. ER expression (100% 
of tumor tissue samples) was observed in patients 
without metastases in RLN. HER2/neu expression 
was noted in somewhat lower number of cases (83%). 
Even less number of studied tumors samples (67%) 
were PR positive.
In case of RLN metastases, different frequency 
of expression of steroid hormone receptors in the 
primary tumors was noted. Namely, ER and PR ex-
pression was detected in 75% of cases in the group 
of patients with RLN N1 status. This was higher in com-
parison with patients with RLN N3 (50%). The statistical 
analysis showed the existence of an inverse correla-
tion between RLN status and ER, PR and HER2/neu 
expression in a primary tumor.
The relation between the receptors expression (ER, 
PR) and HER2/neu and the age of patients in case 
of secondary oncology onset was also analyzed. 
In particular, the age of patients with positive recep-
tor status (ER+PR+HER2/neu+) was higher in case 
of secondary oncology disease onset in comparison 
with the absence of expression of these molecules.
Thus, secondary cancer occurred at the age 
of 63.9 years in patients with ER-positive BC. This was 
about 6 years higher on average compared to a group 
of patients (57.5 years) with ER-negative primary 
tumors. The same regularity was noted in patients 
with PR and HER-positive BC. It should be noted that 
the development of metachronous cancer occurred 
10 years later in patients with HER2/neu-positive 
BC in comparison with patients with HER2/neu-ne-
gative BC (Table 6).
Table 6. Expression of immunohistochemical markers in tumor tissue of pri-
mary ВС and average age of development of metachronous ЕС or ОС
Markers Positive expression of markers Negative expressionAverage age of patients, years
RE 63.9 ± 1.2 57.5 ± 1.0
RP 64.2 ± 4.1 60.2 ± 3.5
HER2/neu 67.3 ± 2.2 57.9 ± 2.7
The statistical analysis of the data indicated the 
correlation between ER expression and the stage of the 
tumor process, RLN status, HER2/neu expression and 
RLN status in BC patients. The relation between the 
molecular subtype of BC and metastasis in RLN was 
also detected.
CONCLUSION
The BC cases with metachronous EC and OC are 
characterized by a different frequency of BC molecular 
subtypes with the dominance of luminal A (36%) and 
B (43%) subtypes. Statistical analysis of the obtained 
results revealed correlation between the different 
clinical characteristics of the BC. In the primary 
BC, we have established a correlation between 
ER expression and RLN status (r = −0.50, p < 0.05); 
negative correlation between HER2 / neu expression 
and stage (r = −0.48, p <0.05); between the molecular 
subtype of BC and its size (r = −0.33, p < 0.05), the 
molecular subtype of primary BC and metastases 
in RLN (r = 0.27, p < 0.05). The highest frequency 
of metastases is noted in patients with triple negative 
BC. In the patients with luminal subtype BC metachro-
nous tumors developed with the highest frequency. 
Metachronous tumors developed at different period 
after treatment of primary tumors: EC (22.2%) — 
most often in 3–5 years, OS (11%) — most often after 
10 years or more. Our data evidence on the clinical 
significance of the individual characteristics of the 
BC, especially its molecular subtype and the need 
to calculate the personalized risk of development 
of metachronous tumors of the reproductive system 
in patients with the BC.
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